GlycoTherapeutics
PrivateLast Round
Grant
Jul 10, 2025
Total Funding Raised
$2.37M
Company Overview
GlycoTherapeutics operates in Healthcare & Life Sciences and is based in Nijmegen. Its latest recorded funding round was a Grant round in April 2023.
GlycoTherapeutics is a biotechnology company that develops anticancer drugs targeting glycans to overcome efficacy limitations in cancer immunotherapies.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
GlycoTherapeutics Comparables
Compare GlycoTherapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Valora Therapeutics Inc. | 84% | |
| Tacalyx | 83% | |
| Adaptam Therapeutics | 81% |
For institutional investors. Book with your work email.
GlycoTherapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Jul 10, 2025 | ||||
| Grant | Apr 26, 2023 | ||||
| Grant | Feb 14, 2023 | ||||
| Grant | Jan 1, 2022 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
GlycoTherapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Province of Gelderland | Grant |
| KWF Dutch Cancer Society | Grant |
| Radboud University | Pre Seed |
| The Launch | Pre Seed |
| Netherlands Organization for Scientific Research | Grant |
| Oost NL | Pre Seed, Grant |
| East Netherlands Development Agency (Oost NL) | Grant |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Feb 17, 2026
Grew 200% QoQ, from 2 to 6 employees.
- Jul 10, 2025
Received grant funding to support operations.
For institutional investors. Book with your work email.
GlycoTherapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about GlycoTherapeutics's valuation, stock price, and market status.
Is GlycoTherapeutics a public or private company?
GlycoTherapeutics is a private company.
What is the current stock price of GlycoTherapeutics?
GlycoTherapeutics is a private company, so its shares have no public market price. Caplight tracks GlycoTherapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is GlycoTherapeutics worth (valuation)?
Valuation information for GlycoTherapeutics is not publicly available.
Can I buy GlycoTherapeutics stock?
GlycoTherapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was GlycoTherapeutics's last funding round?
GlycoTherapeutics's most recent funding round was Grant on July 10, 2025.
Who are the main investors in GlycoTherapeutics?
Key investors in GlycoTherapeutics include KWF Dutch Cancer Society, Netherlands Organization for Scientific Research, East Netherlands Development Agency (Oost NL).
Will GlycoTherapeutics IPO soon?
No public IPO plans have been announced for GlycoTherapeutics.
How can I track GlycoTherapeutics secondary market activity?
Caplight tracks bids, offers, and trades in GlycoTherapeutics's shares on secondary markets.